Table 1.
Characteristics of studies included in the systematic review and meta-analysis.
| Study | Registration | No. of patients | Country | Mean age (% male)a | Intervention | Dosage and administration | Dose classification | Control | Mortality outcomes |
|---|---|---|---|---|---|---|---|---|---|
| DEXA-COVID 19 (WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020)c | NCT04325061 | 19 | Spain | 62 (57.1) | Dexamethasone | 20 mg/d for 5 days and then 10 mg/d for 5 days | High | Usual care | 28-day |
| CoDEX (Tomazini et al., 2020) | NCT04327401 | 299 | Brazil | 62.7 (65.6) | Dexamethasone | 20 mg/d for 5 days and then 10 mg/d for 5 days | High | Usual care | 28-day |
| RECOVERY (RECOVERY Collaborative Group et al., 2021) | NCT04381936 | 1007 | UK | 65.8 (64) | Dexamethasone | 6 mg/d for up to 10 days | Low | Usual care | 28-day |
| Jamaati (2021) (Jamaati et al., 2021) | IRCT20151227025726N17 | 50 | Iran | 62 (72) | Dexamethasone | 20 mg/d for 5 days and then 10 mg/d for 5 days | High | Usual care | 28-day |
| CAPE COVID (Dequin et al., 2020) | NCT02517489 | 149 | France | 66.3 (68.5) | Hydrocortisone | 200 mg/d for 4 d or 7 d, then 100 mg/d for 2 days or 4 days and 50 mg/d for 2 days or 3 days | Low | Placebo | 21-day |
| COVID STEROID (Munch et al., 2021)c | NCT04348305 | 29 | Denmark | Not applicable | Hydrocortisone | 200 mg/d for 7 days | Low | Placebo | 28-day |
| REMAP-CAP (Angus et al., 2020) | NCT02735707 | 197 | Multiple countries b | 59.9 (71.3) | Hydrocortisone | 50 mg every 6 h for 7 days | Low | Usual care | 28-day |
| Steroids-SARI (WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020)c | NCT04244591 | 47 | China | 62 (78) | Methylprednisolone | 40 mg twice daily for 5 days | High | Usual care | 30-day |
| Ranjbar (2021) (Ranjbar et al., 2021) | IRCT20200204046369N1 | 86 | Iran | 61.3 (52.4) | Methylprednisolone | 2 mg/kg per day for 10 days | High | Dexamethasone (6 mg per day for 10 days); Low | 28-day |
| Jeronimo (2021) (Jeronimo et al., 2021) | NCT04343729 | 393 | Brazil | 57 (64.3) | Methylprednisolone | 0.5 mg/kg twice daily for 5 days | Low | Placebo | 28-day |
| Tang (2021) (Tang et al., 2021) | NCT04273321 | 86 | China | 55 (46.5) | Methylprednisolone | 1 mg/kg per day for 7 days | Low | Placebo | In-hospital |
| GLUCOCOVID (Corral-Gudino et al., 2021) | 2020-001934-37 | 64 | Spain | 66 (55) | Methylprednisolone | 40 mg twice daily for 3 days, followed by 20 mg twice daily for another 3 days | High | Usual care | 28-day |
| Edalatifard 2020 (Edalatifard et al., 2020) | IRCT20200404046947N1 | 62 | Iran | 61.7 (53.6) | Methylprednisolone | 250 mg per day for 3 days | High | Usual care | In-hospital |
| Salvarani (2022) (Salvarani et al., 2022) | NCT04673162 | 301 | Italy | 64.0 (70.7) | Methylprednisolone | 1 g per day for 3 days | High | Placebo | 28-day |
| Soliman (2022) (Soliman et al., 2022) | NCT04909918 | 60 | Egypt | 58.1 (46.7) | Methylprednisolone | 1 mg/kg/ per day for 7 days | Low | Dexamethasone (8 mg per day for 7 days); Low | 7-day |
| Dastenae 2022 (Dastenae et al., 2022) | IRCT20210223050466N1 | 143 | Iran | 64.5 (58.6) | Methylprednisolone | 60 mg/ per day for 7 days | Low | Dexamethasone (8 mg per day for 10 days); Low | 28-day |
a
This data was extracted from control group.
b
Australia, Canada, European Union, New Zealand, UK, US.
c
Age was presented in median.